{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:51:20Z","timestamp":1767973880339,"version":"3.49.0"},"reference-count":56,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Testosterone levels in men begin declining in the early years of adulthood, with a 1-2%\nreduction\/year. Low testosterone levels in men are associated with obesity, metabolic syndrome, diabetes\nmellitus, dyslipidaemia, hypertension and increased cardiovascular mortality. However, observational\nstudies of testosterone levels in males and their relationship with peripheral arterial disease (PAD) have\nyielded mixed results; only some cohorts show a clear association with low free testosterone levels. This\ndiscrepancy may, in part, be due to methodological issues with estimating free testosterone but also to\ndifferent effects of testosterone on the vessel wall and metabolism. While testosterone improves\nglycaemic control, has anti-obesity effects and induces vasodilation, it also stimulates platelet aggregation\nand increases the haematocrit. Androgen deprivation treatment for advanced prostate cancer may be\nassociated with elevated cardiovascular risk, as is testosterone abuse for performance enhancement. On\nthe other hand, judicious treatment of male hypogonadism or testosterone treatment of trans-men\nappears to be safe.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161121666230809143023","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T04:33:16Z","timestamp":1691641996000},"page":"297-303","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Testosterone and Peripheral Arterial Disease"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7538-1595","authenticated-orcid":true,"given":"Ale\u0161","family":"Blinc","sequence":"first","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerit Holger","family":"Schernthaner","sequence":"additional","affiliation":[{"name":"Department of Medicine 2, Division of\nAngiology, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Poredo\u0161","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[{"name":"Unit of Reproductive Endocrinology, 1st Department of\nObstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"},{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katica Bajuk","family":"Studen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"},{"name":"Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Antignani","sequence":"additional","affiliation":[{"name":"Vascular Centre Nuova Villa Claudia, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[{"name":"Department of Surgical Biotechnology, Division of Surgery and Interventional Science,\nUniversity College London Medical School, University College London (UCL), London, UK"},{"name":"Department of Clinical Biochemistry, Royal Free Hospital Campus (UCL), London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u0161o","family":"\u0160abovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1161\/01.HYP.0000151825.36598.36","volume":"45","author":"Reckelhoff J.F.","year":"2005","unstructured":"Reckelhoff J.F.; Sex steroids, cardiovascular disease, and hypertension: Unanswered questions and some speculations. Hypertension 2005,45(2),170-174","journal-title":"Hypertension"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fphys.2012.00089","volume":"3","author":"Lopes R.A.M.","year":"2012","unstructured":"Lopes R.A.M.; Neves K.B.; Carneiro F.S.; Tostes R.C.; Testosterone and vascular function in aging. Front Physiol 2012,3,89","journal-title":"Front Physiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/MOU.0000000000000440","volume":"27","author":"Akerman J.","year":"2017","unstructured":"Akerman J.; Kovac J.R.; Lipshultz L.I.; Testosterone therapy improves well being and psychological health. Curr Opin Urol 2017,27(6),519-524","journal-title":"Curr Opin Urol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/1570161121666230516141319","volume":"21","author":"Poredo\u0161 P.","year":"2023","unstructured":"Poredo\u0161 P.; Schernthaner G.H.; Blinc A.; Endocrine disorders and peripheral arterial disease - a series of reviews, 1 - Introduction. Curr Vasc Pharmacol 2023,21(3),147-148","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1210\/jcem.84.10.6122","volume":"84","author":"Negro-Vilar A.","year":"1999","unstructured":"Negro-Vilar A.; Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999,84(10),3459-3462","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1161\/01.CIR.91.4.1154","volume":"91","author":"Yue P.","year":"1995","unstructured":"Yue P.; Chatterjee K.; Beale C.; Poole-Wilson P.A.; Collins P.; Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995,91(4),1154-1160","journal-title":"Circulation"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tips.2007.04.004","volume":"28","author":"Miller V.","year":"2007","unstructured":"Miller V.; Mulvagh S.; Sex steroids and endothelial function: Translating basic science to clinical practice. Trends Pharmacol Sci 2007,28(6),263-270","journal-title":"Trends Pharmacol Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2013.12.010","volume":"233","author":"Vlachopoulos C.","year":"2014","unstructured":"Vlachopoulos C.; Ioakeimidis N.; Miner M.; Testosterone deficiency: A determinant of aortic stiffness in men. Atherosclerosis 2014,233(1),278-283","journal-title":"Atherosclerosis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2015.05.065","volume":"194","author":"Corrigan F.E.","year":"2015","unstructured":"Corrigan F.E.; Al Mheid I.; Eapen D.J.; Low testosterone in men predicts impaired arterial elasticity and microvascular function. Int J Cardiol 2015,194,94-99","journal-title":"Int J Cardiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/ATVBAHA.111.232876","volume":"32","author":"Empen K.","year":"2012","unstructured":"Empen K.; Lorbeer R.; D\u00f6rr M.; Association of testosterone levels with endothelial function in men: results from a population-based study. Arterioscler Thromb Vasc Biol 2012,32(2),481-486","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.hjc.2018.06.001","volume":"59","author":"Antonopoulos A.S.","year":"2018","unstructured":"Antonopoulos A.S.; Antoniades C.; Mechanisms of testosterone deficiency-related endothelial dysfunction. Hellenic J Cardiol 2018,59(4),207-208","journal-title":"Hellenic J Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.hjc.2017.10.004","volume":"59","author":"Tsikas D.","year":"2018","unstructured":"Tsikas D.; Kinzel M.; Associations between asymmetric dimethylarginine (ADMA), nitrite-dependent renal carbonic anhydrase activity, and plasma testosterone levels in hypogonadal men. Hellenic J Cardiol 2018,59(4),201-206","journal-title":"Hellenic J Cardiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41443-019-0163-6","volume":"32","author":"Sansone A.","year":"2020","unstructured":"Sansone A.; Rastrelli G.; Cignarelli A.; Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis. Int J Impot Res 2020,32(4),379-386","journal-title":"Int J Impot Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1161\/01.CIR.91.11.2742","volume":"91","author":"Ajayi A.A.L.","year":"1995","unstructured":"Ajayi A.A.L.; Mathur R.; Halushka P.V.; Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995,91(11),2742-2747","journal-title":"Circulation"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1210\/jc.2009-2575","volume":"95","author":"Fern\u00e1ndez-Balsells M.M.","year":"2010","unstructured":"Fern\u00e1ndez-Balsells M.M.; Murad M.H.; Lane M.; Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010,95(6),2560-2575","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamainternmed.2019.5135","volume":"180","author":"Walker R.F.","year":"2020","unstructured":"Walker R.F.; Zakai N.A.; MacLehose R.F.; Association of testosterone therapy with rRisk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med 2020,180(2),190-197","journal-title":"JAMA Intern Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"101622","DOI":"10.1016\/j.beem.2022.101622","volume":"36","author":"Huhtaniemi I.T.","year":"2022","unstructured":"Huhtaniemi I.T.; Wu F.C.W.; Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism. Best Pract Res Clin Endocrinol Metab 2022,36(4),101622","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/1047-2797(92)90012-F","volume":"2","author":"Khaw K.T.","year":"1992","unstructured":"Khaw K.T.; Barrett-Connor E.; Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992,2(5),675-682","journal-title":"Ann Epidemiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.2337\/db09-0031","volume":"58","author":"Haring R.","year":"2009","unstructured":"Haring R.; V\u00f6lzke H.; Felix S.B.; Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009,58(9),2027-2031","journal-title":"Diabetes"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0943","volume":"162","author":"Vikan T.","year":"2010","unstructured":"Vikan T.; Schirmer H.; Nj\u00f8lstad I.; Svartberg J.; Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol 2010,162(4),747-754","journal-title":"Eur J Endocrinol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/HJR.0b013e32833c1a8d","volume":"18","author":"Haring R.","year":"2011","unstructured":"Haring R.; Baumeister S.E.; V\u00f6lzke H.; Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil 2011,18(1),86-96","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/er.2003-0005","volume":"24","author":"Liu P.Y.","year":"2003","unstructured":"Liu P.Y.; Death A.K.; Handelsman D.J.; Androgens and cardiovascular disease. Endocr Rev 2003,24(3),313-340","journal-title":"Endocr Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1210\/jc.2016-3580","volume":"102","author":"Grossmann M.","year":"2017","unstructured":"Grossmann M.; Matsumoto A.M.; A perspective on middle-aged and older men with functional hypogonadism: Focus on holistic management. J Clin Endocrinol Metab 2017,102(3),1067-1075","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/andr.12135","volume":"4","author":"Calder\u00f3n B.","year":"2016","unstructured":"Calder\u00f3n B.; G\u00f3mez-Mart\u00edn J.M.; Vega-Pi\u00f1ero B.; Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. Andrology 2016,4(1),62-67","journal-title":"Andrology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/eurheartj\/ehq009","volume":"31","author":"Haring R.","year":"2010","unstructured":"Haring R.; V\u00f6lzke H.; Steveling A.; Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010,31(12),1494-1501","journal-title":"Eur Heart J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/cen.12503","volume":"81","author":"Muraleedharan V.","year":"2014","unstructured":"Muraleedharan V.; Hugh Jones T.; Testosterone and mortality. Clin Endocrinol 2014,81(4),477-487","journal-title":"Clin Endocrinol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.cjco.2021.05.007","volume":"3","author":"Kaur H.","year":"2021","unstructured":"Kaur H.; Werstuck G.H.; The Effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: A review of clinical and preclinical data. CJC Open 2021,3(10),1238-1248","journal-title":"CJC Open"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0039-128X(97)00103-7","volume":"62","author":"Price J.F.","year":"1997","unstructured":"Price J.F.; Lee A.J.; Fowkes F.G.R.; Steroid sex hormones and peripheral arterial disease in the Edinburgh Artery Study. Steroids 1997,62(12),789-794","journal-title":"Steroids"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1210\/jc.2011-1068","volume":"96","author":"Haring R.","year":"2011","unstructured":"Haring R.; Travison T.G.; Bhasin S.; Relation between sex hormone concentrations, peripheral arterial disease, and change in ankle-brachial index: Findings from the Framingham Heart Study. J Clin Endocrinol Metab 2011,96(12),3724-3732","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jacc.2007.04.088","volume":"50","author":"Tivesten \u00c5.","year":"2007","unstructured":"Tivesten \u00c5.; Mellstr\u00f6m D.; Jutberger H.; Low serum testosterone and high serum estradiol associate with lower extremity peripheral arte-rial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol 2007,50(11),1070-1076","journal-title":"J Am Coll Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"bvaa038","DOI":"10.1210\/jendso\/bvaa038","volume":"4","author":"Collet T.H.","year":"2020","unstructured":"Collet T.H.; Ewing S.K.; Ensrud K.E.; Endogenous testosterone levels and the risk of incident cardiovascular events in elderly men: The MrOS prospective study. J Endocr Soc 2020,4(5),bvaa038","journal-title":"J Endocr Soc"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.atherosclerosis.2012.09.014","volume":"225","author":"Maggio M.","year":"2012","unstructured":"Maggio M.; Cattabiani C.; Lauretani F.; The relationship between sex hormones, sex hormone binding globulin and peripheral artery disease in older persons. Atherosclerosis 2012,225(2),469-474","journal-title":"Atherosclerosis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/S2666-7568(22)00001-0","volume":"3","author":"Islam R.M.","year":"2022","unstructured":"Islam R.M.; Bell R.J.; Handelsman D.J.; Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. Lancet Healthy Longev 2022,3(2),e109-e118","journal-title":"Lancet Healthy Longev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1743-6109.2010.01705.x","volume":"7","author":"Hern\u00e1ndez-Mijares A.","year":"2010","unstructured":"Hern\u00e1ndez-Mijares A.; Garc\u00eda-Malpartida K.; Sol\u00e1-Izquierdo E.; Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010,7(1),954-964","journal-title":"J Sex Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1210\/jc.2009-1696","volume":"95","author":"Yeap B.B.","year":"2010","unstructured":"Yeap B.B.; Hyde Z.; Norman P.E.; Chubb S.A.P.; Golledge J.; Associations of total testosterone, sex hormone-binding globulin, calculated free testosterone, and luteinizing hormone with prevalence of abdominal aortic aneurysm in older men. J Clin Endocrinol Metab 2010,95(3),1123-1130","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0300-595X(75)80045-4","volume":"4","author":"Brooks R.V.","year":"1975","unstructured":"Brooks R.V.; 1 Androgens. Clin Endocrinol Metab 1975,4(3),503-520","journal-title":"Clin Endocrinol Metab"},{"key":"ref=37","unstructured":"Mayo Clinic Laboratories Testosterone, total, bioavailable, and free serum Available from:"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/er.2017-00025","volume":"38","author":"Goldman A.L.","year":"2017","unstructured":"Goldman A.L.; Bhasin S.; Wu F.C.W.; Krishna M.; Matsumoto A.M.; Jasuja R.; A reappraisal of testosterone\u2019s binding in circulation: Physiological and clinical implications. Endocr Rev 2017,38(4),302-324","journal-title":"Endocr Rev"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","volume":"3","author":"Hudson J.","year":"2022","unstructured":"Hudson J.; Cruickshank M.; Quinton R.; Adverse cardiovascular events and mortality in men during testosterone treatment: An individual patient and aggregate data meta-analysis. Lancet Healthy Longev 2022,3(6),e381-e393","journal-title":"Lancet Healthy Longev"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/13685538.2018.1468429","volume":"21","author":"Groti K.","year":"2018","unstructured":"Groti K.; \u017duran I.; Antoni\u010d B.; For\u0161nari\u010d L.; Pfeifer M.; The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male 2018,21(3),158-169","journal-title":"Aging Male"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1210\/er.2017-00234","volume":"39","author":"Snyder P.J.","year":"2018","unstructured":"Snyder P.J.; Bhasin S.; Cunningham G.R.; Lessons from the testosterone trials. Endocr Rev 2018,39(3),369-386","journal-title":"Endocr Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"CD000188","DOI":"10.1002\/14651858.CD000188.pub2","volume":"10","author":"Price J.","year":"2012","unstructured":"Price J.; Leng G.C.; Steroid sex hormones for lower limb atherosclerosis. Cochrane Libr 2012,10(10),CD000188","journal-title":"Cochrane Libr"},{"key":"ref=43","unstructured":"US Food and Drug Administration. Drug safety communication: FDA\tcautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of\theart attack and stroke with use.  Available from:"},{"key":"ref=44","unstructured":"European Medicines Agency No consistent evidence of an increased risk of heart problems with testosterone medicines Available from :","journal-title":"European Medicines Agency No consistent evidence of an increased risk of heart problems with testosterone medicines"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ahj.2021.11.016","volume":"245","author":"Bhasin S.","year":"2022","unstructured":"Bhasin S.; Lincoff A.M.; Basaria S.; Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J 2022,245,41-50","journal-title":"Am Heart J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/17446651.2023.2197059","volume":"18","author":"Fink J.","year":"2023","unstructured":"Fink J.; Horie S.; Novel methods for the treatment of low testosterone. Expert Rev Endocrinol Metab 2023,18(3),221-229","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11886-021-01561-9","volume":"23","author":"Boland J.","year":"2021","unstructured":"Boland J.; Choi W.; Lee M.; Lin J.; Cardiovascular toxicity of androgen deprivation therapy. Curr Cardiol Rep 2021,23(8),109","journal-title":"Curr Cardiol Rep"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"Keating N.L.","year":"2006","unstructured":"Keating N.L.; O\u2019Malley A.J.; Smith M.R.; Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006,24(27),4448-4456","journal-title":"J Clin Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"Albertsen P.C.","year":"2014","unstructured":"Albertsen P.C.; Klotz L.; Tombal B.; Grady J.; Olesen T.K.; Nilsson J.; Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014,65(3),565-573","journal-title":"Eur Urol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/curroncol28050289","volume":"28","author":"Gheorghe G.S.","year":"2021","unstructured":"Gheorghe G.S.; Hodorogea A.S.; Ciobanu A.; Nanea I.T.; Gheorghe A.C.D.; Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer. Curr Oncol 2021,28(5),3331-3346","journal-title":"Curr Oncol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"Lopes R.D.","year":"2021","unstructured":"Lopes R.D.; Higano C.S.; Slovin S.F.; Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: The primary results of the PRONOUNCE randomized trial. Circulation 2021,144(16),1295-1307","journal-title":"Circulation"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1210\/er.2013-1058","volume":"35","author":"Pope H.G.","year":"2014","unstructured":"Pope H.G.; Wood R.I.; Rogol A.; Nyberg F.; Bowers L.; Bhasin S.; Adverse health consequences of performance-enhancing drugs: An Endocrine Society scientific statement. Endocr Rev 2014,35(3),341-375","journal-title":"Endocr Rev"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.2772","author":"Saetereng T","year":"2021","unstructured":"Saetereng T; Vanberg P; Steine K; Atar D; Halvorsen S; Cardiovascular\trisk associated with long-term anabolic-androgenic steroid abuse: An observational study from Norway. Eur Heart J 2021(S1):ehab724.2772.2021","journal-title":"Eur Heart J"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11154-018-9454-3","volume":"19","author":"Irwig M.S.","year":"2018","unstructured":"Irwig M.S.; Cardiovascular health in transgender people. Rev Endocr Metab Disord 2018,19(3),243-251","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.7326\/M17-0577","volume":"167","author":"Streed C.G.","year":"2017","unstructured":"Streed C.G.; Harfouch O.; Marvel F.; Blumenthal R.S.; Martin S.S.; Mukherjee M.; Cardiovascular disease among transgender adults receiving hormone therapy: A narrative review. Ann Intern Med 2017,167(4),256-267","journal-title":"Ann Intern Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/HYPERTENSIONAHA.119.13080","volume":"74","author":"Connelly P.J.","year":"2019","unstructured":"Connelly P.J.; Marie Freel E.; Perry C.; Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension 2019,74(6),1266-1274","journal-title":"Hypertension"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666230809143023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/219591\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666230809143023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:38:46Z","timestamp":1702471126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/219591\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161121666230809143023","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}